Ultragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.58) per share and revenue of $145.98 million for the quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The business had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, analysts expect Ultragenyx Pharmaceutical to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Trading Up 0.3 %

NASDAQ RARE traded up $0.12 during midday trading on Tuesday, hitting $38.10. The company had a trading volume of 51,523 shares, compared to its average volume of 814,247. Ultragenyx Pharmaceutical has a twelve month low of $29.59 and a twelve month high of $60.37. The company has a market capitalization of $3.58 billion, a PE ratio of -5.98 and a beta of 0.61. The firm has a 50-day moving average price of $37.79 and a 200-day moving average price of $43.54.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the sale, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,643 shares of company stock valued at $5,256,268. 5.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on RARE shares. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. HC Wainwright reiterated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler lowered their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Finally, Canaccord Genuity Group boosted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.